rituximab group:rituximab

3 trials

Sponsors

Department of Pediatrics, Peking University First Hospital, Peking University Third Hospital, The Second People's Hospital of Shenzhen

Conditions

MOG-IgG associated diseasemembranous nephropathyminimal change disease (MCD)

Phase 4

Treatment responses of azathiopurine, mortimecofenate, rituximab and IVIg in children with relapsing myelin oligodendrocyte glycoprotein antibody–associated disease

RecruitingChiCTR2100048742

Department of Pediatrics, Peking University First HospitalMOG-IgG associated disease

Start: 2021-08-01Updated: 2023-01-23

Unknown Phase

Efficacy and safety of low-dose rituximab in the treatment of membranous nephropathy

Active, not recruitingChiCTR2200057381

Peking University Third Hospitalmembranous nephropathy

Start: 2022-03-01Updated: 2023-10-16

Efficacy of rituximab in the treatment of adult minimal change disease - a multicenter two-way cohort study

Active, not recruitingChiCTR2200064434

The Second People's Hospital of Shenzhenminimal change disease (MCD)

Start: 2022-10-08Updated: 2023-05-15

Related Papers

Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach

BMC Nephrology2023-05-2613 citations